Source: Pharmacy Times articles
Treatment decisions should depend on the patient, their disease, and their disease progression.
Read More
Recent Content
- (no title)
- Tecvayli-Darzalex Faspro combo up for approval in 2 nations for treating RRMM
- In vivo CAR-T exhibits activity in advanced multiple myeloma
- FDA backs faster development of new therapy for hard-to-treat AML
- The efficacy and safety of anti-CD38 monoclonal antibodies in transplant-ineligible newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials
- Predictive values of baseline 18F-FDG PET/CT for toxicities and outcomes in patients with relapsed or refractory multiple myeloma following BCMA CAR T-cell therapy
- Correction: Chen et al. The Efficacy and Safety of Tandem Transplant Versus Single Stem Cell Transplant for Multiple Myeloma Patients: A Systematic Review and Meta-Analysis. Diagnostics 2024, 14, 1030
- Comparison of Standard of Care with or Without a PD-1/PD-L-1 Inhibitor for the Treatment of Multiple Myeloma: A Systematic Review and Meta-Analysis of Phase II and III Randomized Controlled Trials
- Combo treatment may offer new hope to astrocytoma patients: Trial
- Reduced-versus Standard-dose Melphalan as Single-agent Conditioning Regimen in Auto HSCT for Multiple Myeloma: A Systematic Review and Meta-Analysis